Benitec Biopharma (ASX: BLT)

Benitec Biopharma (ASX: BLT) is a biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi.

Benitec Biopharma ASX BLT licensing deal Axovant Sciences oculopharyngeal muscular dystrophy drug

Benitec Biopharma secures multimillion-dollar licensing deal with Axovant Sciences

Biopharmaceutical company Benitec Biopharma (ASX: BLT) has decided to licence exclusive global rights to its proprietary oculopharyngeal muscula...
Benitec Biopharma ASX BLT Russia oncology study Phase 2

Benitec Biopharma receives Russian regulatory approval for oncology study

Biopharmaceutical company Benitec Biopharma (ASX: BLT) is well on its way to generating clinical trial results for its potentially ground-breaki...
Benitec Biopharma ASX BLT FDA orphan drug oculopharyngeal muscular dystrophy

Benitec’s BB-301 muscular dystrophy drug granted FDA orphan status

Benitec Biopharma (ASX: BLT) has received orphan drug designation from the FDA for its BB-301 which has been created to treat oculopharyngeal mu...
Benitec Biopharma BLT ASX US patent hepatitis B treatment

Benitec Biopharma secures US patent for hepatitis B treatment

Biotechnology company Benitec Biopharma (ASX: BLT) has secured a US patent for its hepatitis B treatment, which, if successfully developed, coul...